Drew Janice Suzann 4

What Happened
Drew Janice Suzann, Chief of Development Operations at Evommune, was granted 73,892 derivative shares on 2026-04-16. The reported acquisition price is $0.00, indicating no cash was paid at grant (this is a derivative award such as options or RSUs rather than an open-market purchase or sale).

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-17 (appears timely).
• Amount: 73,892 derivative shares; reported price: $0.00; total cash exchanged: $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting (footnote): 25% vests on the first anniversary of the grant; remaining shares vest in 36 equal monthly installments thereafter (i.e., a four‑year schedule with a one‑year cliff).
• No indication of immediate sale or tax withholding reported in the excerpt.

Context
This is a standard employee equity grant, typically used to align incentives and retain staff. Because the award vests over time and no shares were sold, it does not represent an immediate market transaction. Such grants are common and do not by themselves indicate a buy/sell signal.